Study Will Explore Early Detection of Atrial Fibrillation to Reduce Stroke and Heart Failure Risk Through Home Blood Pressure ...
New data presented at ACC 2026 clarifies sotatercept’s role alongside vasodilator-based regimens in PAH patients.
A long-term extension trial of 389 patients found Attruby significantly cut death risk in transthyretin amyloid ...
BACKGROUND: With the increasing diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) at earlier stages and new ...
A machine learning model using routine clinical data more accurately predicted 5-year heart failure risk in patients with CKD ...
Early and continuous treatment with acoramidis is linked to lower risks for death and heart-related hospitalization than delayed treatment in patients with transthyretin amyloid cardiomyopathy.
Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p - Acoramidis mitigated the rise in NT-proBNP through Month 54 to an extent not seen in the era ...
The TARTAN-HF trial found one in four of patients with diabetes who had at least one other risk factor for heart failure had ...
Unique in its focus on adolescents, the trial shows the cardiac myosin inhibitor safely reduces LVOT in the pediatric ...
Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p- Acoramidis mitigated the rise in NT-proBNP through Month 54 to an extent ...
The lack of a dose-response effect could be due to the high number of dropouts in the higher-dose Winrevair arm and the relatively small study population, a discussant for Merck explained.
A major UK-led study has found that undiagnosed heart failure (HF) can be detected in people with high-risk diabetes using a simple, community-based care pathway. The TARTAN-HF trial, run by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results